作者
Raquel González, Tacilta Nhampossa, Ghyslain Mombo-Ngoma, Johannes Mischlinger, Meral Esen, André-Marie Tchouatieu, Anete Mendes, Antía Figueroa-Romero, Lia Betty Dimessa, Bertrand Lell, Heimo Lagler, Rella Zoleko-Manego, Myriam El Galooul, Sergi Sanz, Linda Stöger, Mireia Piqueras, Esperança Sevene, Michael Ramharter, Francisco Saute, Clara Menendez
发表日期
2023/12/1
来源
BMJ Global Health
卷号
8
期号
Suppl 10
出版商
BMJ Specialist Journals
简介
Background
Malaria during pregnancy is an important driver of maternal and neonatal health especially among HIV-infected women. In Africa, at least one million pregnant women are annually co-infected with Plasmodium and HIV. The interaction between the two infections is particularly deleterious during pregnancy, leading to an increased risk of malaria and HIV viral load. Intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine is recommended for malaria prevention in HIV-uninfected women but it is contraindicated in those HIV-infected women on cotrimoxazole prophylaxis (CTXp).
Methods
A randomized, double-blind, two-arm, placebo-controlled trial to evaluate the safety and efficacy of dihydroartemisinin-piperaquine (DHA-PPQ) for IPTp was conducted in HIV-infected pregnant women receiving CTXp, antiretroviral drugs and long lasting insecticide treated nets in five sites …